Patents by Inventor Max H. Schreier

Max H. Schreier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080286281
    Abstract: Administration of monoclonal antibodies specific for IL-2R to xenograft recipients, or long-term to immunosuppression-intolerant or non-compliant patients over a period of time beyond the very early phase of organ transplantation, prevents transplant rejection.
    Type: Application
    Filed: July 28, 2008
    Publication date: November 20, 2008
    Inventors: Gilles Feutren, Richard Kimberley Howell, Peter Marbach, Andrew Roberts, Max H. Schreier, Karin Schreier, Daniel Mark Schreier, Anja Bettina Schreier, Manfred Schulz
  • Publication number: 20020110558
    Abstract: Use of a CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His, said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly, and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe, in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.
    Type: Application
    Filed: January 25, 2001
    Publication date: August 15, 2002
    Inventors: Peter Lloyd Amlot, Max H. Schreier, Karin Schreier
  • Publication number: 20010041179
    Abstract: Administration of monoclonal antibodies specific for IL-2R to xenograft recipients, or long-term to immunosuppression-intolerant or non-compliant patients over a period of time beyond the very early phase of organ transplantation, prevents transplant rejection.
    Type: Application
    Filed: May 22, 2001
    Publication date: November 15, 2001
    Inventors: Gilles Feutren, Richard Kimberley Howell, Peter Marbach, Andrew Roberts, Max H. Schreier, Karin Schreier, Daniel Mark Schreier, Anja Bettina Schreier, Manfred Schulz
  • Patent number: 5169773
    Abstract: Novel monoclonal antibodies capable of distinguishing between cyclosporins, e.g. Cyclosporine, and metabolites, e.g. Cyclosporins 17 and 18, are produced, e.g. starting from novel cyclosporins having an activated coupling group, e.g. activated carboxy group, e.g. (i) [(O-succinimidooxysuccinyl)-Thr].sup.2 -Cyclosporine and (ii) [(N-.epsilon.-succinimidooxysuccinyl)-(D)Lys].sup.8 -Cyclosporine. Cyclosporin starting materials required for the production of cyclosporins of type (ii), e.g. [(D)Lys].sup.8 -Cyclosporine are also new and additionally have utility in the preparation of novel labelled cyclosporin derivatives, as well as antibodies and antisera generally. Also claimed are novel antigenic conjugates and hybridoma cell lines used in the production of antibodies and antisera as aforesaid as well as assay kits comprising novel antisera, antibodies and/or labelled cyclosporins as aforesaid.
    Type: Grant
    Filed: October 31, 1988
    Date of Patent: December 8, 1992
    Assignee: Sandoz Ltd.
    Inventors: Joachim Rosenthaler, Roland Wenger, Philipp E. Ball, Max H. Schreier, Valerie Quesniaux
  • Patent number: 5116816
    Abstract: Cyclic peptolides having the structure of a cyclosporin in which one amide linkage is replaced by an ester linkage are obtained by fermentation of fungal strains of the genus Cylindrotrichum Bonorden, or by cyclization of a hydroxy-undecapeptide. The cyclic peptolides have immunosuppressive, anti-inflammatory and anti-parasitic properties.
    Type: Grant
    Filed: June 20, 1988
    Date of Patent: May 26, 1992
    Assignee: Sandoz Ltd.
    Inventors: Michael M. Dreyfuss, Max H. Schreier, Hans Tscherter